Brief: Ipsen: Phase III Bold Trial Of Bylvay In Biliary Atresia Doesn't Meet Primary Endpoint

Ipsen SA

24/07/2026 06:01

July 24 (Reuters) - Ipsen SA IPN.PA:
PROVIDES UPDATE ON PHASE III BOLD TRIAL IN BILIARY ATRESIA
TOPLINE DATA CONSISTENT WITH SAFETY PROFILE OF ODEVIXIBAT IN APPROVED INDICATIONS
PHASE III BOLD TRIAL OF BYLVAY IN BILIARY ATRESIA DID NOT MEET PRIMARY ENDPOINT
OPEN-LABEL EXTENSION STUDY BOLD-EXT ONGOING FOR LONG-TERM SAFETY AND EFFICACY OF ODEVIXIBAT
Source text: ID:nGNE3Tp8v6
Further company coverage: IPN.PA

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))